News

In 2010, NewLink Genetics licensed Ebola vaccine candidate from its original developer the Public Health Agency of Canada’s National Microbiology Laboratory. Merck and NewLink have entered into an

Elocta is a long-acting recombinant factor VIII Fc fusion protein product candidate designed for patients with haemophilia A. Haemophilia is an inherited condition that regulates the blood’s ability

In this new oncology venture, VIB will become a shareholder alongside ThromboGenics, which will be the majority shareholder. ThromboGenics CEO Dr Patrik De Haes said: "The formation of

The deal will improve Hi-Tech’s Dietary Supplements and OTC product offering as well as expand its distribution through APN’s established platform. The transaction accelerates international growth strategy as

The Vancomycin 10g package is an addition to the company’s Vancomycin 5g pharmacy bulk package offering. The product is indicated to treat serious or severe infections caused by

The agency has issued the Prescription Drug User Fee Act (PDUFA) goal date in December 2015 for a decision on this NDA. The NDA seeks FDA approval of

Copanlisib is an intravenous pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against both PI3K-d and PI3K-a isoforms. The program now includes two new Phase III trials

Gencarois, the company’s investigational, pharmacologically unique beta-blocker and mild vasodilator, is indicated for heart failure patients with reduced left ventricular ejection fraction (HFREF). Currently, Gencaro is being evaluated

As part of the deal, Boehringer is responsible for the global development and commercialization of the new inhibitors, while Hydra will receive an undisclosed upfront payment, additional research